摘要【目的】探讨戈舍瑞林联合比卡鲁胺间歇性治疗对前列腺癌(PC)患者前列腺抗原及免疫功能的影响。【方法】85例晚期PC患者根据入院时间先后顺序分为观察组43例和对照组42例,观察组患者接受戈舍瑞林联合比卡鲁胺间歇性治疗,对照组接受戈舍瑞林联合比卡鲁胺连续性治疗。比较治疗前及治疗后3、6、9、12个月时两组前列腺抗原、血管内皮生长因子(VEGF)、免疫功能变化及不良反应。【结果】治疗后3、6、9、12个月时,两组患者血清前列腺特异性抗原(PSA)、游离前列腺特异抗原(F-PSA)含量均明显低于治疗前(P＜0.05),VEGF含量显著低于治疗前(P＜0.05),外周血中CD3+、CD4+、CD4/CD8淋巴细胞的含量明显高于治疗前,CD8+淋巴细胞亚群的含量明显低于治疗前(P＜0.05),但两组间上述各指标比较差异无显著性(P＞0.05);两组不良反应发生率比较差异无显著性(6.98% vs 11.90%)(P＞0.05)。【结论】戈舍瑞林联合比卡鲁胺间歇性治疗的疗效与连续性治疗相当,均能有效降低PSA含量并调节患者免疫功能。
Abstract：【Objective】To study the effect of goserelin combined with bicalutamide intermittent treatment on prostate specific antigen and immune function of prostate cancer(PC) patients. 【Methods】A total of 85 patients with advanced PC were divided into the observation group (43 cases) and the control group (42 cases). Patients in the observation group received goserelin and bicalutamide intermittent treatment, while patients in the control group received goserelin and bicalutamide treatment continuously. Prostate specific antigen (PSA), vascular endothelial growth factor (VEGF), immune function, and adverse reactions before treatment and 3, 6, 9 and 12 months after treatment were compared between the two groups. 【Results】After 3 months, 6 months, 9 months, and 12 months treatment, serum PSA, F-PSA and VEGF in two groups were significantly lower than those before treatment (P＜0.05). The content of CD3+, CD4+T, and ratio of CD4/CD8 in peripheral blood were significantly higher than those before treatment(P＜0.05), while the content of CD8+ was signficantly lower than that before treatment(P＜0.05).However, there were no statistical differences of PSA, F-PSA, VEGF, CD3+, CD4+T, CD4/CD8 and CD8+ in the two groups(P＞0.05); And there were no statistical difference of adverse reactions between the two groups (6.98% vs 11.90%)(P＞0.05). 【Conclusion】The efficacy of goserelin combined with bicalutamide by means of intermittent treatment is comparable to that of continuous treatment, which can effectively reduce the concentrations of PSA and regulate immune function.
王岩. 戈舍瑞林联合比卡鲁胺间歇性治疗对前列腺癌患者前列腺抗原及免疫功能的影响[J]. 医学临床研究, 2017, 34(8): 1495-1497.
WANG Yan. Effect of Goserelin Combined with Bicalutamide Intermittent Treatment on Prostate Specific Antigen and Immune Function of Prostate Cancer Patients. JOURNAL OF CLINICAL RESEARCH, 2017, 34(8): 1495-1497.
[1]韩苏军,张思维,陈万青,等. 中国前列腺癌发病现状和流行趋势分析[J].临床肿瘤学杂志,2013,18(4):330-334. [2] 庞宽,周泽光,黄英凡,等.比卡鲁胺联合戈舍瑞林治疗晚期前列腺癌的临床疗效及安全性评价[J].中国临床药理学杂志,2016,32(3):224-226. [3] Dean JP, Sprenger CC, Wan J,et al.Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation [J].J Clin Endocrinol Metab,2013, 98(5): E820-828. [4] Nozawa M, Inagaki T, Nagao K,et al.Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naive prostate cancer with bone metastasis [J].Int J Clin Oncol,2014, 19(4):693-701. [5] 陈志雄,李黎明,刘晓龙,等.晚期前列腺癌间歇性和持续性内分泌治疗的效果比较及生活质量分析[J].山东医药,2015,55(25):75-77. [6] 李刚.放射性核素骨显像联合血清学指标在前列腺癌骨转移中的诊疗价值[J].海南医学院学报,2013,19(12):1767-1770. [7] Ragnum HB, Re K, Holm R, et al. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer [J].Int J Radiat Oncol Biol Phys,2013, 87(4):753-760. [8] 吴成爱,刘聪雅,杨永生,等.前列腺癌经直肠超声造影定量参数及分化程度与微血管密度相关性的初步研究[J].中华超声影像学杂志,2015,24(10):865-868. [9] 苟荣,郭淑丽,罗先道. 157例前列腺癌患者细胞免疫功能的变化及意义[J].中国热带医学,2015,15(6):728-730. [10] 朱煜,张建平,许乐,等.比卡鲁胺治疗中晚期前列腺癌的疗效及安全性分析[J].中国医院用药评价与分析,2010,10(3):2.
2017, Vol. 34 
